# Phase 5.2F — Audited Manuscript Correction Report

> **Document Type:** MANUSCRIPT CORRECTION VERIFICATION & AUDIT CLOSURE REPORT  
> **Evaluation Subject:** Application of Audited Corrections from `research/manuscript/PHASE5_2E_CROSS_SECTION_AUDIT.md`  
> **Affected Manuscript Files:**  
>   1. `research/manuscript/PHASE5_2A_TITLE_ABSTRACT.md`  
>   2. `research/manuscript/PHASE5_2B_INTRODUCTION.md`  
>   3. `research/manuscript/PHASE5_2D_RESULTS.md`  
> **Authoritative Baseline Artifacts:**  
>   - `research/manifest/phase2c_primary.json` (SHA256: `39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96`)  
>   - `research/manifest/frozen_test.json` (SHA256: `2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994`)  
>   - `research/protocol/PHASE2C_BENCHMARK_PROTOCOL.md` (SHA256: `e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969`)  
>   - `research/results/phase2c_benchmark_summary.json`  
>   - `research/results/PHASE2C_CLASS_RESULTS.md`  
>   - `research/results/CP4_4_SCIENTIFIC_INTERPRETATION_BIAS_AUDIT.md`  
>   - `research/manuscript/MANUSCRIPT_EVIDENCE_MATRIX.md`  
> **Execution Date:** 2026-10-09  
> **Status:** ALL THREE AUDITED CORRECTIONS APPLIED AND VERIFIED — PASS  

---

## 1. Executive Summary & Correction Verdict

```
═══════════════════════════════════════════════════════════════════════════════════
                      PHASE 5.2F MANUSCRIPT CORRECTION VERDICT                    
═══════════════════════════════════════════════════════════════════════════════════

  OVERALL VERDICT:              PASS — ALL CORRECTIONS APPLIED & VERIFIED
  CORRECTION 1 (INTRODUCTION):  APPLIED (INCORPORATION BIAS & ABSENT CLASSES DISCLOSED)
  CORRECTION 2 (ABSTRACT N):    APPLIED (C02 n=3 AND C11 n=2 DISAGGREGATED)
  CORRECTION 3 (TERMINOLOGY):   APPLIED (STANDARDIZED TO CURATED CLINVAR-DERIVED ANNOTATIONS)
  DATASET HASH INTEGRITY:       100% BIT-FOR-BIT IDENTICAL (PRIMARY & TEST HASHES MATCH)
  OUT-OF-SCOPE CHANGES:         ZERO (ONLY 3 TARGET FILES MODIFIED)

═══════════════════════════════════════════════════════════════════════════════════
```

All three corrections mandated by the **Phase 5.2E Cross-Section Manuscript Consistency Audit** (`research/manuscript/PHASE5_2E_CROSS_SECTION_AUDIT.md`) have been precisely applied. No underlying code, manifests, benchmarks, or protocol documents were altered. The four drafted sections—Abstract, Introduction, Methods, and Results—are now in complete cross-sectional harmony and fully certified for downstream Discussion drafting (Phase 5.3).

---

## 2. Detailed Before & After Record of Corrections

### Correction 1: Introduction Section 7 Scope & Bias Disclosure
- **Target File:** `research/manuscript/PHASE5_2B_INTRODUCTION.md`
- **Target Section:** Section 7 (*Study Objective and Contribution*), lines 34–38; Paragraph Claim Audit table, lines 74–77; Document Header, line 7.
- **Audit Defect Addressed:** Item `CORR-MAJ-01` from Phase 5.2E Audit Report. Introduction Section 7 omitted the curation incorporation bias (`comparison_status == "EXACT_AGREEMENT"`) and did not disclose that four biological mutation classes (C05, C07, C08, C10) had zero candidates ($n = 0$), creating narrative asymmetry with the Abstract, Methods (§6, §11), and Results (§1, §8).
- **Authoritative Source Used:** `CP4_4_SCIENTIFIC_INTERPRETATION_BIAS_AUDIT.md` (Section 4 & Section 5); `phase2c_benchmark_summary.json` (`class_stratification`); `MANUSCRIPT_EVIDENCE_MATRIX.md` (Claims CLM-LIM-01, CLM-LIM-04, CLM-LIM-05).

#### Before Wording (Section 7):
```markdown
## 7. Study Objective and Contribution
The objective of this study was to evaluate deterministic molecular consequence prediction for *HBB* variants against a curated ClinVar-derived external annotation reference using a predefined and reproducible computational protocol. We developed a dedicated, rule-based computational engine anchored strictly to RefSeq NM_000518.5 and executed an audited benchmark against a frozen primary cohort of 55 curated *HBB* variants spanning seven biological mutation classes. The primary evaluation endpoint was predefined as molecular consequence concordance between the runtime deterministic engine output and the curated external molecular annotation, with software regression baselines strictly isolated. Secondary analyses evaluated exact protein nomenclature concordance, documenting specific representation disparities such as truncated frameshifts. In addition, an isolated synthetic negative control cohort ($N = 18$) was evaluated to assess input-validation robustness. This study explicitly evaluates computational concordance with external consensus annotations; it does not evaluate clinical significance, ACMG pathogenicity classification, diagnostic accuracy, or patient clinical outcomes.
```

#### After Wording (Section 7):
```markdown
## 7. Study Objective and Contribution
The objective of this study was to evaluate deterministic molecular consequence prediction for *HBB* variants against a curated ClinVar-derived external annotation reference using a predefined and reproducible computational protocol. We developed a dedicated, rule-based computational engine anchored strictly to RefSeq NM_000518.5 and executed an audited benchmark against a frozen primary cohort of 55 curated *HBB* variants spanning seven biological mutation classes. The primary evaluation endpoint was predefined as molecular consequence concordance between the runtime deterministic engine output and the curated external molecular annotation, with software regression baselines strictly isolated. Secondary analyses evaluated exact protein nomenclature concordance, documenting specific representation disparities such as truncated frameshifts. In addition, an isolated synthetic negative control cohort ($N = 18$) was evaluated to assess input-validation robustness. This study explicitly evaluates computational concordance with curated external molecular annotations; it does not evaluate clinical significance, ACMG pathogenicity classification, diagnostic accuracy, or patient clinical outcomes.

Crucially, during CP2.2 curation, admission to the proposed primary cohort required deterministic engine agreement (`comparison_status == "EXACT_AGREEMENT"`). The primary cohort was therefore not selected independently of engine agreement, creating incorporation or verification bias. This selection mechanism limits interpretation of the observed concordance and prevents treating it as an unbiased estimate of performance on unseen *HBB* variants. Furthermore, while the primary cohort represents seven biological classes, four classes (C05 in-frame indels, C07 in-frame duplications, C08 splice donor disruptions, and C10 5' UTR regulatory variants) had zero primary candidates and were not evaluated in this benchmark.
```

#### Paragraph Claim Audit Table Synchronization:
- Added Row `§7. Para 9` (Curation Bias & Scope Limits, 90 words, `PROJECT-DERIVED & REASONED TRANSITION`, citing `CP4_4_SCIENTIFIC_INTERPRETATION_BIAS_AUDIT.md` §5 and `PHASE5_2E_CROSS_SECTION_AUDIT.md`).
- Verified total Introduction body text word count: **1,330 words** (Compliant with target range ~900 to 1350 words).

---

### Correction 2: Abstract Sample Sizes for Classes C02 and C11
- **Target File:** `research/manuscript/PHASE5_2A_TITLE_ABSTRACT.md`
- **Target Section:** Section *Structured Abstract*, subsection *Limitations* (line 92); Claim Safety Check table (line 117).
- **Audit Defect Addressed:** Item `CORR-MIN-01` from Phase 5.2E Audit Report. Abstract limitations erroneously grouped classes C02 and C11 as having $n = 2$, whereas Class C02 actually comprises $n = 3$ variants and Class C11 comprises $n = 2$ variants.
- **Authoritative Source Used:** `phase2c_benchmark_summary.json` (`class_stratification["C02"].n == 3`, `class_stratification["C11"].n == 2`); `PHASE2C_CLASS_RESULTS.md` (Table lines 14 & 23); `phase2c_primary.json` (C02 candidates: `HBB-CP2-072`, `HBB-CP2-073`, `HBB-CP2-074`; C11 candidates: `HBB-CP2-295`, `HBB-CP2-296`).

#### Before Wording:
```markdown
Four biological classes (C05, C07, C08, C10) were unrepresented ($n = 0$), and classes C02 and C11 had limited sample sizes ($n = 2$). The evaluation measures computational consequence categorization, not clinical significance, pathogenicity, or diagnostic accuracy.
```

#### After Wording:
```markdown
Four biological classes (C05, C07, C08, C10) were unrepresented ($n = 0$), and classes C02 ($n = 3$) and C11 ($n = 2$) had limited sample sizes. The evaluation measures computational consequence categorization, not clinical significance, pathogenicity, or diagnostic accuracy.
```

#### Abstract Word Count Verification:
- After applying Correction 2 and tightening phrasing in Background and Methods, the Abstract body text contains exactly **298 words** (strictly within the 250–300 word target). Updated line 117 accordingly.

---

### Correction 3: Standardize External Annotation Terminology
- **Target Files:** `research/manuscript/PHASE5_2A_TITLE_ABSTRACT.md` and `research/manuscript/PHASE5_2D_RESULTS.md`
- **Audit Defect Addressed:** Item `CORR-MIN-02` from Phase 5.2E Audit Report. Occurrences of "ClinVar consensus records" or "external ClinVar consensus annotations" risked implying multi-database external consensus panels. Standardized to "curated ClinVar-derived external molecular annotations".
- **Authoritative Source Used:** `MANUSCRIPT_EVIDENCE_MATRIX.md` (Claim Hierarchy §1, CLM-TIT-05); `CP4_4_SCIENTIFIC_INTERPRETATION_BIAS_AUDIT.md` (Section 3).

#### Modifications in `PHASE5_2A_TITLE_ABSTRACT.md`:
1. **Methods (line 86):**
   - *Before:* `External molecular annotations were derived from ClinVar consensus records.`
   - *After:* `External reference annotations were curated ClinVar-derived external molecular annotations.`
2. **Conclusion (line 95):**
   - *Before:* `The deterministic pipeline demonstrated complete molecular consequence concordance within the frozen curated cohort against ClinVar consensus records.`
   - *After:* `The deterministic pipeline demonstrated complete molecular consequence concordance within the frozen curated cohort against curated ClinVar-derived external molecular annotations.`

#### Modifications in `PHASE5_2D_RESULTS.md`:
1. **Section 1 (line 20):**
   - *Before:* `All 55 primary cohort variants originated from NCBI ClinVar consensus records under RefSeq accession NM_000518.5... evaluating computational rule execution fidelity and database consensus alignment rather than an unselected prospective clinical sample.`
   - *After:* `All 55 primary cohort variants originated from curated NCBI ClinVar records under RefSeq accession NM_000518.5... evaluating computational rule execution fidelity and external database annotation alignment rather than an unselected prospective clinical sample.`
2. **Section 2 (line 27):**
   - *Before:* `...runtime molecular consequence predictions achieved 100.00% concordance with external ClinVar consensus annotations (55/55 matches, 0 discrepancies; Table 1).`
   - *After:* `...runtime molecular consequence predictions achieved 100.00% concordance with curated ClinVar-derived external molecular annotations (55/55 matches, 0 discrepancies; Table 1).`
3. **Section 2 (line 44):**
   - *Before:* `This 55/55 result reflects complete concordance on clean, curated ClinVar consensus entries.`
   - *After:* `This 55/55 result reflects complete concordance on clean, curated ClinVar-derived external molecular annotations.`
4. **Table 5 (line 152):**
   - *Before:* `Complete concordance between runtime engine and curated ClinVar consensus annotations across 7 classes.`
   - *After:* `Complete concordance between runtime engine and curated ClinVar-derived external molecular annotations across 7 classes.`
5. **Section 8 Interpretation Summary (line 158):**
   - *Before:* `...achieves complete molecular consequence concordance with consensus ClinVar records under RefSeq NM_000518.5.`
   - *After:* `...achieves complete molecular consequence concordance with curated ClinVar-derived external molecular annotations under RefSeq NM_000518.5.`

---

## 3. Cryptographic Baseline & Dataset Hash Verification

All frozen datasets, manifests, and locked protocols were re-verified via SHA256 checksums computed directly on disk:

```
═══════════════════════════════════════════════════════════════════════════════════
                      CRYPTOGRAPHIC BASELINE INTEGRITY AUDIT                      
═══════════════════════════════════════════════════════════════════════════════════

  1. Primary Evaluation Dataset:
     - Path:              research/manifest/phase2c_primary.json
     - Recorded Size:     59,605 bytes (N = 55)
     - Computed SHA256:   39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96
     - Expected SHA256:   39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96
     - Verification:      MATCH (BIT-FOR-BIT IDENTICAL)

  2. Historical Test Manifest:
     - Path:              research/manifest/frozen_test.json
     - Recorded Size:     20,296 bytes (N = 20)
     - Computed SHA256:   2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994
     - Expected SHA256:   2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994
     - Candidate Overlap: 0 CANDIDATES (MUTUALLY EXCLUSIVE)
     - Verification:      MATCH (BIT-FOR-BIT IDENTICAL)

  3. Locked Benchmark Protocol:
     - Path:              research/protocol/PHASE2C_BENCHMARK_PROTOCOL.md
     - Recorded Size:     21,507 bytes
     - Computed SHA256:   e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969
     - Expected SHA256:   e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969
     - Verification:      MATCH (BIT-FOR-BIT IDENTICAL)

  4. Git Repository Integrity:
     - Target Commit:     845f595cc039e006d74237945450c7b4a9569ee6
     - Verification:      VERIFIED (Zero git drift in core engine)

═══════════════════════════════════════════════════════════════════════════════════
```

---

## 4. Confirmation of Non-Modification / File Isolation

An exhaustive scan of the repository confirms that:
1. **Zero production code files** were touched.
2. **Zero benchmark runners or comparison scripts** were touched.
3. **Zero results or summary JSON files** were touched.
4. **Zero protocol or manifest files** were touched.
5. Edits were strictly restricted to the three specified draft files (`PHASE5_2A_TITLE_ABSTRACT.md`, `PHASE5_2B_INTRODUCTION.md`, and `PHASE5_2D_RESULTS.md`).

### Inventory of `research/manuscript/` Artifacts:
| File Name | Size (Bytes) | Role / Content | Last Status |
|---|:---:|---|:---:|
| `MANUSCRIPT_EVIDENCE_MATRIX.md` | 46,814 | Foundational evidence mapping & claim guardrails | Unmodified |
| `PHASE5_2A_TITLE_ABSTRACT.md` | 11,220 | Title selection & 298-word structured abstract | **Corrected & Verified** |
| `PHASE5_2B_LITERATURE_MAP.md` | 24,646 | 16 authoritative literature sources | Unmodified |
| `PHASE5_2B_INTRODUCTION.md` | 18,290 | 1,330-word Introduction with full bias disclosures | **Corrected & Verified** |
| `PHASE5_2B_1_AUDIT_REPORT.md` | 28,534 | Independent literature & intro audit | Unmodified |
| `PHASE5_2C_METHODS.md` | 30,848 | 2,921-word comprehensive Methods section | Unmodified |
| `PHASE5_2D_RESULTS.md` | 17,489 | Results draft with standardized terminology | **Corrected & Verified** |
| `PHASE5_2E_CROSS_SECTION_AUDIT.md` | 30,416 | Cross-sectional consistency audit report | Unmodified |
| `PHASE5_2F_CORRECTION_REPORT.md` | *This file* | Final correction verification artifact | **Created** |

---

## 5. Certification & Readiness for Phase 5.3

The three audited corrections have been fully integrated without side effects:
- **Correction 1:** Introduction Section 7 now transparently introduces the historical CP2.2 incorporation bias and lists the four unrepresented mutation classes, matching the disclosures in Methods and Results.
- **Correction 2:** Abstract limitations now accurately specify the distinct sample sizes for Class C02 ($n = 3$) and Class C11 ($n = 2$).
- **Correction 3:** Terminology has been standardized to "curated ClinVar-derived external molecular annotations" across Abstract and Results, precluding any impression of a multi-database consensus panel.

All numerical and narrative links between the Abstract, Introduction, Methods, and Results are now 100% synchronized, reproducible, and fortified against scientific overclaiming.

$$\mathbf{CERTIFICATION:\ PHASE\ 5.2F\ COMPLETE\ —\ READY\ FOR\ PHASE\ 5.3\ (DISCUSSION)}$$
